The reiteration of an Overweight rating and maintenance of a $365 price target by Cantor Fitzgerald analyst Olivia Brayer indicates a positive outlook for Vertex Pharmaceuticals. This could lead to increased investor confidence and a potential short-term increase in the stock price.